Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gut bacteriophages are viruses that specifically infect bacteria residing within the gastrointestinal tract. They represent the most abundant viral entities in the human gut ecosystem, where they play crucial roles in shaping microbial community structure by lysing specific bacterial populations, facilitating horizontal gene transfer, and influencing overall microbial diversity. The "gut bacteriophage profile" refers not to a single molecular target but rather to the collective population structure—also called the "phageome"—of these viruses within an individual's digestive tract. These profiles are highly individualized and can be temporally stable yet responsive to environmental factors such as diet or antibiotic use. Bacteriophages have been explored as therapeutic agents ("phage therapy") for treating multidrug-resistant bacterial infections due to their specificity for certain pathogens while sparing commensal flora. Their ability to disrupt biofilms further enhances their therapeutic potential compared to conventional antibiotics. However, their role is double-edged; imbalances or shifts in phage populations have been implicated in various intestinal disorders through mechanisms involving altered metabolite release from lysed bacteria and direct activation of host immunity. Despite growing interest, much about gut bacteriophage biology remains poorly understood—including their full diversity ("viral dark matter"), precise functions within health and disease contexts, optimal methods for profiling them accurately across studies, and long-term safety implications when used therapeutically.[1][3][4][5] **Note:** "Gut bacteriophage profiles" is not a canonical molecular target but rather a descriptive term referring collectively to all phages present in the gut at any given time; it does not denote a single receptor/protein/target suitable for drug development pipelines. Therefore: **is_target:** false **is_incorrect:** true — This entry describes a population-level feature rather than an individual molecule/receptor/enzyme typically considered as a drug target.[1][3][5]
Lysis of specific bacterial hosts via infection and replication within bacteria[1][3][4]; Disruption of biofilms formed by pathogenic bacteria[4]; Modulation of immune responses through direct or indirect interactions with the host immune system[4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut bacteriophage.